Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ONCY
STRONG SELLREMOVEOncolytics Biotech Inc. · Healthcare · United States · $114M · Avg Vol: $1M/d
Oncolytics Biotech is a micro-cap clinical-stage biotechnology firm with no commercialized products or cash flows, failing all core quality and safety metrics.
COMPANY DESCRIPTION
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on the development of pelareorep, an oncolytic virus designed to induce an anti-cancer immune response. The company's unique competitive position lies in leveraging its proprietary virus to treat multiple cancer types in combination with other therapies, aiming to improve patient outcomes through an immunotherapeutic approach.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| EPS | -0.32 | -0.31 | -0.29 | -0.30 | — |
| Shares | 61.3M | 74.4M | 80.0M | 108.0M | +76.1% |
| Debt | 0.3M | 0.3M | 0.8M | 0.6M | 27.0% |
| Equity | 19.5M | 20.8M | 3.3M | -3.8M | -58.9% |
| Op CF | -17.2M | -21.4M | -19.9M | -20.1M | — |
| Inv CF | -15.0M | 15.2M | -0.2M | -6,000 | — |
| Fin CF | 9.0M | 24.1M | 5.0M | 14.1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ONCY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ONCY | Oncolytics Biotech Inc.(you) | $114M | 9 | STRONG SELL |
| KLRS | Kalaris Therapeutics, Inc. | $111M | 8 | STRONG SELL |
| COYA | Coya Therapeutics, Inc. | $123M | 8 | STRONG SELL |
| CNTB | Connect Biopharma Holdings Limited | $126M | 10 | STRONG SELL |
| ANIX | Anixa Biosciences, Inc. | $96M | 9 | STRONG SELL |
| PEPG | PepGen Inc. | $134M | 8 | STRONG SELL |
| CUE | Cue Biopharma, Inc. | $126M | 6 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $87M | 9 | STRONG SELL |
| 2592.HK | Cloudbreak Pharma Inc. | $125M | 5 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $151M | 9 | STRONG SELL |
Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%